Innodem Neurosciences
8
2
2
3
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 8 trials
100.0%
+13.5% vs industry average
0%
0 trials in Phase 3/4
0%
0 of 3 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (8)
Development of a Novel Functional Eye-Tracking Software Application for Multiple Sclerosis
Role: lead
Investigating Eye-Movement Biomarkers of Disease Severity and Cognition in Multiple Sclerosis
Role: lead
ETNA-MS Device Validation Study
Role: lead
Eye-tracking Investigation of Clinical Measures in Multiple Sclerosis
Role: lead
Development and Validation of a Novel Functional Eye-Tracking Software Application for Neurological Disorders
Role: lead
Development and Validation of a Novel Functional Eye-Tracking Software Application for Alzheimer's Disease
Role: lead
Implementation of a Novel Functional Eye-Tracking Biomarker for Multiple Sclerosis
Role: collaborator
Development and Validation of a Novel Functional Eye-Tracking Software Application for Cancer-related Cognitive Impairment (CRCI)
Role: lead
All 8 trials loaded